Results 201 to 210 of about 89,998 (263)

Epigenetic reprogramming of lineage switching in cancer

FEBS Letters, EarlyView.
Cancer cells rarely commit to a single identity. Epigenetic mechanisms and tumor microenvironment cues push epithelial cells toward flexible, hybrid states that can shift into mesenchymal, neuroendocrine, or stem‐like fates, driving metastasis, drug resistance, and tumor heterogeneity. Targeting the epigenetic regulators behind these transitions, using
Ezgi Boyvatlı, Burcu Akman, Ezgi Bağırsakçı, Nese Atabey, Serap Erkek‐Ozhan   +4 more
wiley   +1 more source

Leadless Pacing and the Emerging Era of Combined Procedures in Adult Congenital Heart Disease. [PDF]

JACC Case Rep
Das S, Karolcik BA, Howard TS.
europepmc   +1 more source

The microbiome in human skin aging

FEBS Letters, EarlyView.
Age‐related skin changes encompass the well‐known visible phenotypic alterations, together with microbiome dysbiosis and a series of molecular aging hallmarks. These hallmarks characterize not only a fully stablished aged phenotype but also the skin aging process itself.
Manuel Huerta Arana, Cornelia Wiegand, Omid Omrani, Mario Fabri   +3 more
wiley   +1 more source

From prediction to action-Making emergency laparotomy risk scores clinically usable. [PDF]

Surg Pract Sci
Vijayaraghavalu S.
europepmc   +1 more source

Quantum Computing and Quantum Technologies in Drug Discovery and Therapeutics: Evidence, Benchmarking, and Translational Integration. [PDF]

Drug Des Devel Ther
Niazi SK.
europepmc   +1 more source

Current Clinical Utility of Gene Expression Panels in Primary Cutaneous Melanoma. [PDF]

Cancers (Basel)
Garza TL, Choi JH, McGee M, Box E, Nywening T, Karachristos A, Schwarzberg A, Fishman M, Jacobson R.   +8 more
europepmc   +1 more source

Pharmacogenomic Stratification for Oncology Drug Repurposing: An Exposure Target Context Eligibility Framework. [PDF]

Pharmaceuticals (Basel)
El-Tanani M, Wali AF, Rabbani SA, El-Tanani Y, Rangraze I, Muhana F.   +5 more
europepmc   +1 more source

Re-thinking funding success in Alzheimer's disease research: Why good science is not enough. [PDF]

J Prev Alzheimers Dis
Fusdahl P, Borda MG, Aarsland D.
europepmc   +1 more source

Pharmacotherapy Risks in Rare Genetic Diseases: Cross-Referencing ACMG Secondary Findings v3.2 List With Clinical Databases. [PDF]

Clin Transl Sci
Allen JD, Duong BQ, Vogt J, Arn P.
europepmc   +1 more source